Nuvilex (PMCB) Competitors $0.97 -0.04 (-3.99%) Closing price 04:00 PM EasternExtended Trading$0.97 0.00 (0.00%) As of 05:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PMCB vs. TENX, MDCX, CVKD, RLYB, RNTX, FBLG, RVPH, QTTB, NAII, and NNVCShould you be buying Nuvilex stock or one of its competitors? The main competitors of Nuvilex include Tenax Therapeutics (TENX), Medicus Pharma (MDCX), Cadrenal Therapeutics (CVKD), Rallybio (RLYB), Rein Therapeutics (RNTX), FibroBiologics (FBLG), Reviva Pharmaceuticals (RVPH), Q32 Bio (QTTB), Natural Alternatives International (NAII), and NanoViricides (NNVC). These companies are all part of the "pharmaceutical products" industry. Nuvilex vs. Its Competitors Tenax Therapeutics Medicus Pharma Cadrenal Therapeutics Rallybio Rein Therapeutics FibroBiologics Reviva Pharmaceuticals Q32 Bio Natural Alternatives International NanoViricides Tenax Therapeutics (NASDAQ:TENX) and Nuvilex (NASDAQ:PMCB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation. Do analysts rate TENX or PMCB? Tenax Therapeutics presently has a consensus target price of $17.00, indicating a potential upside of 187.16%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Tenax Therapeutics is more favorable than Nuvilex.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tenax Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Nuvilex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger earnings and valuation, TENX or PMCB? Tenax Therapeutics is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTenax TherapeuticsN/AN/A-$17.60M-$0.92-6.43NuvilexN/AN/A$30.66M$2.590.37 Does the media favor TENX or PMCB? In the previous week, Tenax Therapeutics and Tenax Therapeutics both had 1 articles in the media. Nuvilex's average media sentiment score of 1.64 beat Tenax Therapeutics' score of -0.59 indicating that Nuvilex is being referred to more favorably in the news media. Company Overall Sentiment Tenax Therapeutics Negative Nuvilex Very Positive Do institutionals and insiders have more ownership in TENX or PMCB? 1.7% of Tenax Therapeutics shares are held by institutional investors. Comparatively, 34.2% of Nuvilex shares are held by institutional investors. 3.7% of Tenax Therapeutics shares are held by company insiders. Comparatively, 10.2% of Nuvilex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is TENX or PMCB more profitable? Nuvilex's return on equity of 4.60% beat Tenax Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tenax TherapeuticsN/A -31.34% -30.39% Nuvilex N/A 4.60%3.76% Which has more risk & volatility, TENX or PMCB? Tenax Therapeutics has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500. Comparatively, Nuvilex has a beta of -0.29, suggesting that its share price is 129% less volatile than the S&P 500. SummaryNuvilex beats Tenax Therapeutics on 8 of the 13 factors compared between the two stocks. Get Nuvilex News Delivered to You Automatically Sign up to receive the latest news and ratings for PMCB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PMCB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PMCB vs. The Competition Export to ExcelMetricNuvilexMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.60M$2.48B$5.74B$9.78BDividend YieldN/A1.67%4.40%4.04%P/E Ratio0.3722.5330.8326.39Price / SalesN/A506.55382.9086.63Price / CashN/A178.3537.7259.11Price / Book0.136.2910.106.62Net Income$30.66M$32.94M$3.26B$265.42M7 Day Performance3.67%2.27%3.90%3.58%1 Month Performance1.57%1.06%3.73%0.46%1 Year Performance-34.46%5.65%37.68%19.41% Nuvilex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PMCBNuvilex1.8935 of 5 stars$0.97-4.0%N/A-35.2%$6.60MN/A0.374Gap UpTENXTenax Therapeutics1.4382 of 5 stars$6.02+0.2%$17.00+182.4%+45.0%$27.42MN/A-6.549MDCXMedicus Pharma1.8621 of 5 stars$1.96-2.0%$23.50+1,099.0%N/A$27.15MN/A-1.46N/AGap UpHigh Trading VolumeCVKDCadrenal Therapeutics3.0768 of 5 stars$13.81+5.8%$32.00+131.7%+78.6%$26.71MN/A-1.564RLYBRallybio3.008 of 5 stars$0.57-8.9%$10.00+1,657.5%-47.7%$26.11M$640K-0.6140RNTXRein TherapeuticsN/A$1.10-2.7%N/AN/A$26.04MN/A-0.419Gap UpFBLGFibroBiologics3.3192 of 5 stars$0.59-4.6%$13.00+2,107.1%-63.3%$25.85MN/A-1.6410News CoverageRVPHReviva Pharmaceuticals2.6733 of 5 stars$0.53+2.8%$7.17+1,242.6%-48.2%$24.92MN/A-0.825QTTBQ32 Bio2.8014 of 5 stars$1.81-11.3%$12.17+572.2%-95.3%$24.88M$1.16M-0.4239Positive NewsNAIINatural Alternatives International1.4615 of 5 stars$3.85-0.3%N/A-32.8%$23.85M$113.80M-2.77290Positive NewsNNVCNanoViricides0.2625 of 5 stars$1.44-5.9%N/A-28.5%$23.14MN/A-2.0020News CoverageGap Up Related Companies and Tools Related Companies TENX Competitors MDCX Competitors CVKD Competitors RLYB Competitors RNTX Competitors FBLG Competitors RVPH Competitors QTTB Competitors NAII Competitors NNVC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PMCB) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvilex Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvilex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access